Abstract
A new chromosome-carried quinolone resistance gene from Stenotrophomonas maltophilia, Smqnr, was characterized. The gene was present in type strain CCUG 5866 and was also detected in 24 clinical isolates and showed some allelic diversity. The expression of Smqnr in Escherichia coli decreased the susceptibilities of the E. coli isolates to several fluoroquinolones.
qnr (later termed qnrA1), the first plasmid-mediated quinolone resistance determinant identified, was first reported in 1998 from Klebsiella pneumoniae (7). QnrA1 belongs to the pentapeptide repeat family and protects DNA gyrase and topoisomerase IV from the inhibitory actions of quinolones (10, 11, 12). QnrA1 confers resistance to quinolones and increases the MICs of fluoroquinolones up to 32-fold (8). Since then, several proteins belonging to the Qnr family have been described in members of the family Enterobacteriaceae (6). The source of the plasmid-mediated qnrA genes has been identified in the chromosome of Shewanella algae (9), while the possible source of the plasmid-mediated qnrS determinants was identified in the chromosome of Vibrio splendidus (3).
Stenotrophomonas maltophilia is a nonfermentative gram-negative environmental species that can cause nosocomial infections and that is characterized by intrinsic resistance to several antibiotics (2, 5). In silico analysis of the recently released genome sequence of S. maltophilia strain R551-3 (GenBank accession no. NZ_AAVZ0100006) revealed an open reading frame (SmalDRAFT_0855) coding for a 219-amino-acid protein that shares 61.5% and 61% amino acid identities with QnrB1 and QnrB2, respectively. In this study, we cloned and sequenced the S. maltophila qnr homologue, designated Smqnr, from S. maltophilia CCUG 5866T and 24 epidemiologically unrelated clinical isolates (which mainly originated from respiratory specimens).
The species identities of the S. maltophilia clinical isolates were confirmed by species-specific PCR (13). The nucleotide sequences of the Smqnr alleles were determined by a PCR-based strategy. Primer pair SmQnrX-F (5′-ACACAGAACGGCTGGACTGC-3′) and SmQnrX-R (5′-TTCAACGACGTGGAGCTGTT-3′) amplified an 817-bp fragment containing almost all the Smqnr alleles evaluated in this study. Other primer pairs were also used. Primer pair SmQnrY-F (5′-GATCGGAGCTCATGCTGCAA-3′) and SmQnrY-R (5′-GCAGCGCGCGATCGAAGCAA-3′) amplified a 970-bp fragment containing the Smqnr-1 gene, and primer pair SmQnrZ-F (5′-TCTATGGATCGGCCTCG-3′) and SmQnrZ-R (5′-TTCAGCTTCAAGGGCTGGG-3′) amplified a 745-bp fragment containing the Smqnr-10 gene. The nucleotide sequences and the deduced amino acid sequences were analyzed with GENETYX-MAC software (version 13; GENETYX Corporation, Tokyo, Japan) and the information available on the National Center for Biotechnology Information website (www.ncbi.nih.gov). Multiple-protein-sequence alignments were carried out with the program CLUSTALW (http://clustalw.ddbj.nig.ac.jp/top-j.html).
Sequences related to the Smqnr gene from strain R551-3 were detected both in the type strain and in each of the clinical isolates, suggesting that the gene is ubiquitous in S. maltophilia. Some allelic variability was observed among the Smqnr genes. A total of 11 alleles were identified, and these encoded proteins that differed by up to 20 amino acids at 219 possible sites (9.1%) (Fig. 1).
The amplified PCR fragments containing the 11 different Smqnr alleles identified in this work were cloned into plasmid pCR-4 I-TOPO (Invitrogen, Life Technologies, Carlsbad, CA) to yield recombinant plasmids pSmQnr1, pSmQnr2, pSmQnr3, pSmQnr4, pSmQnr5, pSmQnr6, pSmQnr7, pSmQnr8, pSmQnr9, pSmQnr10, and pSmQnr11, respectively. All recombinant plasmids carried the cloned genes in the same orientation under the transcriptional control of the plasmid Plac promoter flanking the multiple-cloning site. Then, Escherichia coli TOP10 (Invitrogen) derivatives carrying each of these plasmids were used to determine the MICs of quinolone and fluoroquinolones by Etest (AB Biodisk, Solna, Sweden). The MICs were interpreted according to the guidelines of the CLSI (4).
The results are shown in Table 1. Different quinolones and fluoroquinolones MICs were observed among the different allelic variants. These findings are suggestive of the correlation between the amino acid substitutions and the degree of quinolone resistance, but it is still unclear which amino acid substitutions contribute to quinolone resistance.
TABLE 1.
Strain | MIC (μg/ml)b
|
||||||
---|---|---|---|---|---|---|---|
NAL | NOR | LVX | CIP | SPX | GAT | MXF | |
E. coli TOP10 | 1.5 | 0.032 | 0.004 | 0.002 | <0.002 | <0.002 | <0.002 |
E. coli TOP10/pSmQnr1 | 3.0 | 0.064 | 0.023 | 0.008 | 0.004 | 0.008 | 0.012 |
E. coli TOP10/pSmQnr2 | 2.0 | 0.047 | 0.012 | 0.004 | <0.002 | <0.002 | <0.002 |
E. coli TOP10/pSmQnr3 | 1.5 | 0.032 | 0.006 | 0.003 | <0.002 | 0.003 | 0.002 |
E. coli TOP10/pSmQnr4 | 1.5 | 0.032 | 0.006 | 0.002 | <0.002 | 0.002 | 0.002 |
E. coli TOP10/pSmQnr5 | 2.0 | 0.032 | 0.008 | 0.002 | <0.002 | <0.002 | 0.003 |
E. coli TOP10/pSmQnr6 | 2.0 | 0.064 | 0.023 | 0.016 | 0.125 | 0.064 | 0.047 |
E. coli TOP10/pSmQnr7 | 2.0 | 0.047 | 0.023 | 0.008 | 0.008 | 0.023 | 0.008 |
E. coli TOP10/pSmQnr8 | 2.0 | 0.047 | 0.012 | 0.004 | <0.002 | 0.002 | 0.002 |
E. coli TOP10/pSmQnr9 | 1.5 | 0.032 | 0.008 | 0.003 | <0.002 | 0.002 | <0.002 |
E. coli TOP10/pSmQnr10 | 2.0 | 0.032 | 0.023 | 0.004 | 0.002 | 0.003 | 0.004 |
E. coli TOP10/pSmQnr11 | 2.0 | 0.032 | 0.012 | 0.006 | <0.002 | 0.003 | 0.002 |
MICs of quinolone and fluoroquinolones against E. coli TOP10 and E. coli TOP10 harboring recombinant plasmids pSmQnr1, pSmQnr2, pSmQnr3, pSmQnr4, pSmQnr5, pSmQnr6, pSmQnr7, pSmQnr8, pSmQnr9, pSmQnr10, and pSmQnr11.
NAL, nalidixic acid; NOR, norfloxacin; LVX, levofloxacin; CIP, ciprofloxacin; SPX, sparfloxacin; GAT, gatifloxacin; MXF, moxifloxacin.
SmQnr is clearly capable of decreasing quinolone and fluoroquinolone susceptibilities, similar to the other Qnr determinants. However, further studies are required to assess the contribution of Smqnr to the quinolone susceptibility of S. maltophilia, which is also known to be affected by efflux-based mechanisms (1).
Nucleotide sequence accession numbers.
The following nucleotide sequences described in this paper have been submitted to the EMBL/GenBank/DDBJ database under the indicated accession numbers: Smqnr1, AB430839; Smqnr2, AB430840; Smqnr3, AB430841; Smqnr4, AB430842; Smqnr5, AB430843; Smqnr6, AB430849; Smqnr7, AB430845; Smqnr8, AB430850; Smqnr9, AB430846; Smqnr10, AB430847; and Smqnr11, AB430848.
Acknowledgments
This work was supported by a Grant-in Aid for 21st Century COE Research and a Grant-in-Aid for Scientific Research on Priority Areas (grant 13226114) from the Ministry of Education, Science, Sports, Culture, and Technology of Japan.
Footnotes
Published ahead of print on 21 July 2008.
REFERENCES
- 1.Alonso, A., and J. L. Martinez. 2001. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 45:1879-1881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Alonso, A., and J. L. Martinez. 1997. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 41:1140-1142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Cattoir, V., L. Poirel, D. Mazel, C. J. Soussy, and P. Nordmann. 2007. Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. Antimicrob. Agents Chemother. 51:2650-2651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. Document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
- 5.Denton, M., N. J. Todd, K. G. Kerr, P. M. Hawkey, and J. M. Littlewood. 1998. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J. Clin. Microbiol. 35:1953-1958. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Jacoby, G. A., V. Cattoir, D.C. Hooper, L. Martínez-Martínez, P. Nordmann, A. Pascual, L. Poirel, and M. Wang. 2008. qnr gene nomenclature. Antimicrob. Agents Chemother. 52:2297-2299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Martinez-Martinez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797-799. [DOI] [PubMed] [Google Scholar]
- 8.Nordmann, P., and L. Poirel. 2005. Emergency of plasmid-mediated resistance of quinolones in Enterobacteriaceae. J. Antimicrob. Chemother. 56:463-469. [DOI] [PubMed] [Google Scholar]
- 9.Poirel, L., J. M. Rodriqguez-Mrtinez, H. Mammeri, A. Liard, and P. Nordmann. 2005. Origin of plasmid-mediated quinolone resistance determinant QnrA. Antimicrob. Agents Chemother. 49:3523-3525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Tran, J. H., and G. A. Jacoby. 2002. Mechanism of plasmid-mediated quinolone resistance. Proc. Natl. Acad. Sci. USA 99:5638-5642. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Tran, J. H., G. A. Jacoby, and D. C. Hooper. 2005. Interaction of the plasmid-mediated quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob. Agents Chemother. 49:118-125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Tran, J. H., G. A. Jacoby, and D. C. Hooper. 2005. Interaction of the plasmid-mediated quinolone resistance protein Qnr with Escherichia coli topoisomerase IV. Antimicrob. Agents Chemother. 49:3050-3052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Whitby, P. W., K. B. Carter, J.L. Burns, J. A. Royall, J. J. LiPuma, and T. L. Stull. 2000. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J. Clin. Microbiol. 38:4305-4309. [DOI] [PMC free article] [PubMed] [Google Scholar]